Screener
Halozyme Therapeutics HALO Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Other income (expense) | ||||
| Investment and other income, net | 2,836 | 6,891 | 4,154 | 13,709 |
| Interest expense | (5,588) | (4,394) | (11,096) | (8,919) |
| Income before income tax expense | 284,902 | 204,938 | 465,229 | 348,766 |
| Income tax expense | 54,989 | 39,778 | 85,267 | 65,511 |
| Net income | $229,913 | $165,160 | $379,962 | $283,255 |
| Earnings per share | ||||
| Basic | $1.96 | $1.36 | $3.23 | $2.32 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's pre-tax income?
- Halozyme Therapeutics (HALO) reported pre-tax income of $284.9M in Q2 2026.
- How has Halozyme Therapeutics's pre-tax income changed year-over-year?
- Halozyme Therapeutics's pre-tax income increased by 39.0% year-over-year, from $204.94M to $284.9M.
- What is the long-term trend for Halozyme Therapeutics's pre-tax income?
- Over 3 years (2021 to 2024), Halozyme Therapeutics's pre-tax income has grown at a 30.9% compound annual growth rate (CAGR), from $248.52M to $557.13M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Halozyme Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude